Immunization with Sanofi Pasteur’s tetravalent dengue candidate vaccine generated a sero-neutralizing antibody response against all four serotypes of the virus responsible for dengue fever in 100% of adults who participated in a trial in the US.
These results have prompted Sanofi Pasteur to immediately expand ongoing clinical trials in Asia and Latin America. Submission to health authorities for registration is anticipated in 2012.
Sanofi Pasteur’s tetravalent dengue candidate vaccine is based on a new technology incorporating the protein envelopes that provide immunity against the four virus types responsible for dengue fever and the most severe forms of the disease – dengue hemorrhagic fever and dengue shock syndrome.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Sanofi Pasteur made research for a vaccine against dengue fever one of its top priorities by investing in the most promising technology and dedicating top scientists to this lifesaving project. Sanofi Pasteur’s goal is to make dengue fever a vaccine-preventable disease as quickly as possible with a vaccine available to people living in endemic countries or traveling to tropical destinations.”